<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211121053130N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-11</date_registration>
      <primary_sponsor>Fasa University of Medical Sciences</primary_sponsor>
      <public_title>effect of magnesium sulfate on pain and agitation after tonsillectomy</public_title>
      <acronym></acronym>
      <scientific_title>study and compare two different doses of magnesium sulfate in decreasing pain and agitation of children after tonsillectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60143</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: After generating random block sequences by Random  Allocation Software version 1.0.0, the sequences in each block will be placed in numbered envelopes. for each group of patients, we randomly select one of the blocks, the sequences in each block will be used to assign individuals to one of the study groups, Blinding description: preparation of medication and placebo will be performed and labeld as A,B,C by researchers and will be given to OR personel who has no idea about labels meaning. researchers have no role in giving the medication and measuring the outcome. 
As above,Statistical analyzer will analyze the data without the knowledge that each group receive which medication.</study_design>
      <phase>3</phase>
      <hc_freetext>pain and agitation after tonsillectomy in children.</hc_freetext>
      <i_freetext>Intervention 1: Control group: anesthesia induction will be done by administration of midazolam 0.5-1 mg/kg , Atra 0.4-0.6 mg/kg , STP 5-7 mg/kg and fentanyl 2mcg/kg by anesthesiologist.first group as control group will receive no further medication but placebo with same administration method of magnesium sulfate. Intervention 2: first Intervention group: anesthesia induction will be done by administration of midazolam 0.5-1 mg/kg , Atra 0.4-0.6 mg/kg , STP 5-7 mg/kg and fentanyl 2mcg/kg by anesthesiologist.then the will receive  30 mg/kg mg sulfate as loading dose fallowed by 10mg/kg/hr for 1 hour as maintenance dose. Intervention 3: second Intervention group: anesthesia induction will be done by administration of midazolam 0.5-1 mg/kg , Atra 0.4-0.6 mg/kg , STP 5-7 mg/kg and fentanyl 2mcg/kg by anesthesiologist.then the will receive  40 mg/kg mg sulfate as loading dose fallowed by 10mg/kg/hr for 1 hour as maintenance dose.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The decision on releasing the data will be made based on supervisor professrors in future</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Reza Malek Motiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ebne Sina Square</address>
        <city>Fasa</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۶۶۸۸ - ۷۴۶۱۶</zip>
        <telephone>+98 71 5335 0994</telephone>
        <email>Info@fums.ac.ir</email>
        <affiliation>Fasa University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sedighe Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ebne Sina Square</address>
        <city>Fasa</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۶۶۸۸ - ۷۴۶۱۶</zip>
        <telephone>+98 71 5335 0994</telephone>
        <email>Ahmadis@gmail.com</email>
        <affiliation>Fasa University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>consent of patient and parentsASA class I II II
need to do tonsillectomy
ASA class I II II</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>15 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unwillingness to participate in study
ASA class IV
anatomical abnormalities in airway
reoperation due to bleeding
difficult intubation
History of cardiology,renal,respiratory diseases
History of MG</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J35.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hypertrophy of tonsils</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: anesthesia induction will be done by administration of midazolam 0.5-1 mg/kg , Atra 0.4-0.6 mg/kg , STP 5-7 mg/kg and fentanyl 2mcg/kg by anesthesiologist.first group as control group will receive no further medication but placebo with same administration method of magnesium sulfate.</i_keyword>
      <i_keyword>first Intervention group: anesthesia induction will be done by administration of midazolam 0.5-1 mg/kg , Atra 0.4-0.6 mg/kg , STP 5-7 mg/kg and fentanyl 2mcg/kg by anesthesiologist.then the will receive  30 mg/kg mg sulfate as loading dose fallowed by 10mg/kg/hr for 1 hour as maintenance dose</i_keyword>
      <i_keyword>second Intervention group: anesthesia induction will be done by administration of midazolam 0.5-1 mg/kg , Atra 0.4-0.6 mg/kg , STP 5-7 mg/kg and fentanyl 2mcg/kg by anesthesiologist.then the will receive  40 mg/kg mg sulfate as loading dose fallowed by 10mg/kg/hr for 1 hour as maintenance dose</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: 5 minutes after extubation/10 minutes after extubation/15 minutes after extubation/30 minutes after extubation/1hour after extubation/2 hour after extubation/6 hour after extubation/. Method of measurement: FLACC score for pain.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Agitation. Timepoint: 5 minutes after extubation/10 minutes after extubation/15 minutes after extubation/30 minutes after extubation/1hour after extubation/2 hour after extubation/6 hour after extubation/. Method of measurement: Ricker-sedation-agitation score.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Fasa University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-21</approval_date>
        <contact_name>Ethics committee of fasa University of Medical Sciences</contact_name>
        <contact_address>ebne sina square fasa fars fasa Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
